Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer [0.03%]
度伐利尤单抗联合化疗对比帕博利珠单抗联合化疗作为非小细胞肺癌一线治疗的药物经济学分析
Tong Liu,Xin Zhang,Bingjie Liu et al.
Tong Liu et al.
Lung cancer is one of the most common malignant cancers in most countries, and non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Checkpoint inhibitor immunotherapy is the preferred therapy for metastati...
The efficacy and safety analysis of oral isavuconazole therapy of invasive pulmonary aspergillosis [0.03%]
口服艾沙康唑治疗侵袭性肺曲霉病的疗效和安全性分析
Yanli Gu,Rong Zhang,Wei Ding et al.
Yanli Gu et al.
This retrospective study aimed to explore the efficacy and safety of oral isavuconazole in treating invasive pulmonary aspergillosis (IPA). Among 31 enrolled patients, 21 survived and 10 died by the 42-days follow-up. The mean hospitalizati...
Identification of synthetic lethality-associated subtypes and construction of risk model to predict breast cancer prognosis and immune characteristics [0.03%]
合成致死相关亚型的识别及乳腺癌预后和免疫特征预测风险模型的构建
Jianhong Tang,Weihong Chen,Weibao Zou et al.
Jianhong Tang et al.
Synthetic lethality has emerged as a pivotal concept in cancer therapy, offering novel and promising strategies for treatment. In this study, we identified molecular subtypes associated with synthetic lethality in breast cancer and develope...
Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review [0.03%]
帕博利珠单抗治疗期间出现多形性红斑的罕见皮肤表现：一例报告及文献回顾
G Silvi,E Rosi,I Scandagli et al.
G Silvi et al.
We report the case of a 77-year-old man with recurrent oral squamous cell carcinoma who developed erythema multiforme (EM) following his third dose of pembrolizumab (PBZ). The patient presented with a widespread skin rash characterized by e...
Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report [0.03%]
派姆单抗治疗化疗耐药性妊娠滋养细胞肿瘤一例报告
Sercan Ön
Sercan Ön
Gestational trophoblastic neoplasia (GTN) is a rare malignancy that can develop following a hydatidiform mole or a non-molar pregnancy and often presents with metastasis. Although conventional chemotherapy achieves remission in over 90% of ...
Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells [0.03%]
灯盏花甲素通过调节microRNA-149-3p/AFF4轴影响顺铂耐药卵巢癌细胞的增殖和凋亡
Yunfei Liu,Taoli Chen,Yanpeng Wang et al.
Yunfei Liu et al.
Although cinobufagin has been demonstrated to inhibit the growth of various malignant tumors, its functional role in ovarian cancer remains unclear. In light of this, the present study aims to thoroughly investigate the effects of cinobufag...
PqsR-specific quorum sensing inhibitors targeting Pseudomonas aeruginosa: current advances and future directions [0.03%]
针对铜绿假单胞菌的PqsR特异性群体感应抑制剂：当前进展和未来方向
Mandsaurwala Aziz,Kafil Ahmed,Vinothkannan Ravichandran
Mandsaurwala Aziz
The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa is driven by diverse resistance mechanisms, including quorum sensing (QS) and biofilm formation. QS regulates virulence, antibiotic tolerance, efflux pumps, and biofilm devel...
Docetaxel associated myositis [0.03%]
多西他赛肌炎
Nadide Demırel,Metin Demır
Nadide Demırel
Introducti̇on: Docetaxel is a microtubule inhibitor in the taxane group and it is a semisynthetic analogue of paclitaxel. It binds to β-tubulin subunits with high affinity, preventing the depolymerization of microtubule...
NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cells [0.03%]
NCAPG2促进胃腺癌细胞的增殖、转移及白蛋白结合型紫杉醇耐药性
Jia Xu,Xiaoyuan Liu,Zebo Huang et al.
Jia Xu et al.
Gastric adenocarcinoma is one of the most common cancers in the world. The purpose of this study was to investigate the role of non-smooth muscle cell aggregation protein II complex G2 subunit (NCAPG2) in gastric cancer cells. Cell growth, ...
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma [0.03%]
二𫫇英和多西他赛联合疗法可克服KRAS G12C突变肺腺癌对单用二𫫇英的耐药性
Chia-Yu Kuo,Tzu-Wen Wang,Ann-Shung Lieu et al.
Chia-Yu Kuo et al.
Mutations in the KRAS gene are the most common gain-of-function mutations found in lung adenocarcinomas. The most prevalent mutation, KRAS G12C, occurs in 13% of lung adenocarcinomas. Sotorasib is an irreversible small molecule inhibitor th...